2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1694

Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease
Abstract Number: 1695

Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases
Abstract Number: 1696

Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?
Abstract Number: 1697

Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study
Abstract Number: 1698

Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease
Abstract Number: 1699

Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation
Abstract Number: 1700

Clinical Characteristics and the Level Disease Activity of Behcet´s Disease in China: A Study Based on Smart System of Disease Management (SSDM)
Abstract Number: 1701

Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road
Abstract Number: 1702

Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study
Abstract Number: 1703

Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet’s Disease
Abstract Number: 1704

Efficacy of Leflunomide for Treatment of Vasculitis
Abstract Number: 1705

Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?
Abstract Number: 1706

HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease
Abstract Number: 1707

IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Abstract Number: 1708

Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].